Voloridge Investment Management
JANX icon

Voloridge Investment Management’s Janux Therapeutics JANX Stock Holding History

Voloridge Investment Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-55,212
Closed -$2.31M – 1259
2024
Q2 		$2.31M Buy
+55,212
New +$2.59M 0.01% 919

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management's JANX Position: Q3 2024 in Review

Voloridge Investment Management sold out of Janux Therapeutics (JANX) in Q3 2024, closing a stake of 55,212 shares — an estimated $2.31M sold.

Voloridge Investment Management first reported a position in JANX in Q2 2024 and held it in 1 quarter. The position peaked at $2.31M in Q2 2024. 160 funds tracked by Wall St. Rank hold JANX as of Q3 2024.

  • Voloridge Investment Management reported no remaining Janux Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 55,212 Janux Therapeutics shares in Q3 2024, an estimated $2.31M.
  • Voloridge Investment Management first reported a position in Janux Therapeutics in Q2 2024 and held it in 1 quarter.
  • Voloridge Investment Management's Janux Therapeutics position peaked at $2.31M in Q2 2024.
  • 160 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2024.

Based on Voloridge Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.